212
Participants
Start Date
May 26, 2016
Primary Completion Date
October 31, 2019
Study Completion Date
October 31, 2019
DX-2930
Participants who rollover from the DX-2930-03 study will receive 300 milligram (mg) DX-2930 subcutaneous injection at Day 0 followed by second dose following the first HAE attack and then once in every 2 weeks until the end of the treatment period (up to 924 days). A wash-out period of a minimum of 10 days and a maximum of 18 days is required between subsequent administrations.
DX-2930
Participants who were not participants in DX-2930-03 will receive 300 milligram (mg) DX-2930 subcutaneous injection once in every 2 weeks until the end of the treatment period (up to 924 days).
Icahn School of Medicine at Mount Sinai, New York
Charité - Universitätsmedizin Berlin, Berlin
Winthrop University Hospital, Mineola
Triumpharma Clinical Evaluation Centre, Amman
Penn State Hershey Medical Center, Hershey
University of Milan Luigi Sacco Hospital, Milan
Institute Asthma and Allergy, Chevy Chase
Virginia Commonwealth University, Richmond
Duke Asthma, Allergy, and Airway Center, Durham
Clinical Research Center of Charlotte, Charlotte
University of South Florida, Tampa
Clinical Research Center of Alabama, Birmingham
Optimed Research, LTD., Columbus
Toledo Institute of Clinical REsearch, Toledo
Bernstein Clinical Research Center, LLC, Cincinnati
University of Michigan, Ann Arbor
Medical College of Wisconsin, Childrens Hospital, Milwaukee
Hautklinik der Universitätsmedizin Mainz, Mainz
Midwest Immunology Clinic, Plymouth
Universitätsklinikum Frankfurt, Frankfurt
Washington University School of Medicine, St Louis
HZRM Hamophilie Zentrum Rhein Main GmbH, Mörfelden-Walldorf
University of Kansas Medical Center, Kansas City
AARA Research Center, Dallas
Austin Regional Clinic, Austin
IMMUNOe Research Centers, Centennial
Asthma and Allergy Associates, PC, Colorado Springs
Intermountain Clinical Research, Draper
Allergy Associates of Utah, Murray
Medical Research of Arizona, Scottsdale
AIRE Medical of Los Angeles, Santa Monica
University of California San Diego, San Diego
Allergy & Asthma Clinical Research, Walnut Creek
Premier Clinical Research, Spokane
Massachusetts General Hospital, Boston
Hudson-Essex Allergy, LLC, Belleville
Atlantic Research Center, LLC, Ocean City
University of Alberta Hospital, Edmonton
Yang Medicine, Ottawa
Gordon Sussman Clinical Research, Inc., Toronto
Clinique Spécialisée en Allergie de la Capitale, Québec
Adler Medical Plaza, San Juan
Royal London Hospital, London
Lead Sponsor
Shire
INDUSTRY